Eating Less, Spending More on Health: How Obesity Drugs Are Redrawing the Consumer Landscape

Rising demand for solutions to post-weight-loss side effects
Restaurant industry begins overhauling its strategies
GLP-1 effects extending into behavioral change

GLP-1-based obesity medications are reshaping the broader consumer economy far beyond the healthcare sector. As appetite-suppressing effects reduce food consumption, related markets such as hair-loss treatments, protein supplements, and nutritional products are experiencing rapid growth. Food manufacturers are also increasingly pivoting toward smaller portions and high-protein offerings. More recently, discussions have expanded to potential changes in consumer behavior and preferences, positioning obesity drugs as a catalyst for the emergence of an entirely new industrial ecosystem.

The Rise of the GLP-1 Side-Effect Management Industry

According to the pharmaceutical industry on June 5, the hair-loss treatment market has expanded alongside the growing adoption of GLP-1 obesity drugs in the United States. Kerafactor, a company specializing in scalp-care products, reported a 100% year-over-year increase in revenue, while hair-growth supplement brand Nutrafol said the rise in GLP-1 users had contributed positively to sales growth. Data from market research firm Mordor Intelligence showed that the North American hair-loss treatment market reached $1.05 billion last year. The firm projects the market will grow at a compound annual growth rate of 7.15% through 2031, reaching $1.59 billion.

Alongside the expansion of the hair-loss market, demand for gallstone prevention and treatment products has also risen steadily. Rapid weight loss associated with GLP-1 drugs can increase the risk of gallstones. Gallstones occur when components of bile harden into stone-like deposits in the gallbladder, causing pain and inflammation. According to a meta-analysis published in JAMA Internal Medicine that examined 76 clinical trials involving more than 100,000 patients, users of GLP-1 receptor agonists faced a 37% higher risk of gallbladder and biliary diseases than control groups. Among patients using the drugs specifically for weight loss, the risk increased by as much as 2.29 times. Market research firm QY Research forecasts that the ursodiol market, used to treat biliary disorders, will expand from $457 million in 2023 to $944 million by 2030, representing an annual growth rate of 11.1%.

Demand for vitamin and mineral supplements has also increased significantly. Because GLP-1 users consume less food, they may fall short on essential nutrients such as vitamin D, iron, B vitamins, and magnesium. Nutrition experts in the United States are increasingly recommending multivitamin and mineral supplementation for patients using obesity medications over extended periods, fueling growth in the related health supplement market. Demand for digestive health products is also rising. Constipation, abdominal discomfort, and reduced gastrointestinal motility rank among the most frequently reported side effects of GLP-1 drugs. As a result, consumers are increasingly turning to fiber supplements, probiotics, and prebiotics.

Food Companies Reshape Their Portfolios

Obesity drugs are also transforming food consumption patterns. The most direct change is a decline in food intake. Research indicates that users reduce their annual calorie consumption by more than 20% on average, with some cases reporting daily intake reductions of up to 40%. The impact is becoming visible across the restaurant industry. According to research conducted by Cornell University, households using GLP-1 medications reduced spending at fast-food restaurants and coffee shops in the United States by an average of 8%.

More damaging than declining sales is the erosion of the industry's upselling strategy. The U.S. food industry spent much of the 20th century increasing portion sizes, supported by industrialization and declining grain and meat prices following World War II. As a result, the concept of “supersizing” became a defining feature of American dining culture. A study published in the academic journal Foods in 2024 found that typical portion sizes in the United States are 13% larger than those in France. However, the rise of obesity drugs that actively reduce consumption is forcing the food industry to rethink its approach.

Olive Garden, known for its unlimited breadsticks, introduced smaller-portion versions of seven existing menu items across 900 U.S. locations this year. Seafood chain Angry Crab Shack launched lunch offerings featuring smaller baskets containing fried cod, cheeseburgers, lobster rolls, and French fries. Tucci, an upscale Italian restaurant in New York, unveiled an “Ozempic Menu,” reducing both portion sizes and prices by one-third. Founder Max Tucci explained that the goal was not to promote obesity medications but to provide appealing options for customers experiencing reduced appetites.

Major restaurant operators have also begun adapting. Yum Brands, the parent company of KFC, Pizza Hut, and Taco Bell, said KFC is adjusting portion sizes across 4,000 U.S. locations. McDonald’s has shifted its focus toward high-protein marketing rather than simply reducing portions, targeting consumers concerned about muscle loss during weight reduction. Sandwich chain Panera Bread has expanded sales of half sandwiches and smaller salads while promoting the slogan “Eat Less, Eat Better.” A market once dominated by fullness and indulgence is rapidly shifting toward protein-rich, low-sugar offerings.

Changes Extending Beyond Appetite Suppression

As food intake declines, consumer expectations regarding nutritional quality are also rising. According to The Wall Street Journal, users of obesity medications place greater emphasis on protein content, nutrient density, and satiety compared with traditional consumers. Walmart similarly reported that regions with high GLP-1 usage saw declining sales of high-calorie snacks and processed foods, while purchases of fruits, vegetables, yogurt, and high-protein foods increased.

Changes are also emerging in the beverage market. Market research firm NielsenIQ reported that American consumers are reducing their consumption of sugar-laden soft drinks and energy beverages while increasingly choosing protein drinks and functional beverages. Ready-to-drink (RTD) products emphasizing protein content, along with low-sugar and high-fiber offerings, are experiencing particularly rapid growth. As obesity medications absorb demand for weight loss solutions, they are influencing product development strategies across the broader food industry.

The shift extends beyond food choices. Researchers and healthcare professionals are increasingly examining whether GLP-1 medications may affect consumer desires and behavioral patterns themselves. A growing body of research suggests that the drugs influence the brain’s reward pathways while reducing food intake, potentially affecting addictive behaviors related to alcohol, tobacco, gambling, and other activities. In the United States, users have increasingly reported reductions in alcohol consumption and smoking urges after beginning GLP-1 treatment. Some studies are also exploring the drugs’ potential applications in treating alcohol use disorder, substance addiction, and compulsive consumption behaviors.

Industry observers expect these trends to persist. Global pharmaceutical companies are investing heavily in next-generation obesity treatments to sustain the GLP-1 boom. Novo Nordisk, the developer of Wegovy, launched its oral obesity treatment known as “Wegovy Pill” in the U.S. market in January. The drug quickly gained traction, surpassing 50,000 prescriptions within a month of launch. Eli Lilly, the developer of Mounjaro, is also preparing to launch its oral obesity drug orforglipron, which is reportedly expected to be priced at approximately $5 per day. In addition, Eli Lilly is developing retatrutide, a triple-action therapy combining GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG).